No Data
No Data
Oppenheimer Maintains Capricor Therapeutics(CAPR.US) With Buy Rating, Maintains Target Price $14
Oppenheimer analyst Leland Gershell maintains $Capricor Therapeutics(CAPR.US)$ with a buy rating, and maintains the target price at $14.According to TipRanks data, the analyst has a success rate of 0.
Express News | Capricor Therapeutics Files For Mixed Shelf Offering Of Up To $150M
Express News | Capricor Therapeutics Inc Files for Mixed Shelf Offering of up to $150 Mln- SEC Filing
12 Health Care Stocks Moving In Tuesday's After-Market Session
GainersAutonomix Medical (NASDAQ:AMIX) shares moved upwards by 11.1% to $1.3 during Tuesday's after-market session. The company's market cap stands at $24.4 million. Unicycive Therapeutics (NASDAQ:UNC
Sector Update: Health Care Stocks Decline Tuesday Afternoon
Health care stocks were lower Tuesday afternoon, with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund (XLV) each shedding about 0.6%. The iShares Biotechnology ETF (IBB) fell ab
Capricor Says FDA Grants Pre-BLA Meeting Request for Duchenne Muscular Dystrophy Treatment; Shares Rise
Capricor Therapeutics (CAPR) said Tuesday the US Food and Drug Administration has agreed to a pre-biologics license application meeting regarding the company's lead CAP-1002 treatment candidate for Du